Flavamed

Quick links to important sections

Flavamed

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flavamed

Property Description
Active Ingredient Ambroxol Hydrochloride (e.g., 30 mg strength)
Pharmacological Class Mucolytic and Secretolytic Agent
Common Use Relief of productive cough associated with thick mucus
Manufacturer & Status BERLIN-CHEMIE AG (Germany); Often available OTC

Flavamed is a medicinal product centered around the active ingredient, ambroxol hydrochloride, a compound used primarily in the symptomatic management of acute and chronic respiratory conditions that involve abnormal, thick mucus secretion. Ambroxol belongs to the pharmacological class of mucolytics and secretolytics, agents specifically designed to help the body clear mucus from the airways.

This active substance is a metabolite of bromhexine and works by affecting the properties of mucus. It is clinically recognized for its ability to stimulate the synthesis and release of pulmonary surfactant, a natural lung substance that helps reduce the stickiness of mucus and promotes the stability of air sacs.

Pharmacological studies confirm that ambroxol’s mechanism is dual: it thins the thick mucus (secretolytic action) and stimulates the microscopic hair-like structures (cilia) in the airways to sweep the thinned mucus upward (secretomotoric action). This effect on mucus secretion and transport helps to make coughs more productive and less tiring.

Flavamed, manufactured by BERLIN-CHEMIE AG, is often available Over-The-Counter (OTC) in various forms, including scored tablets and syrup, to facilitate use across different age groups, including pediatric patients where appropriate.

What side effects are possible with Flavamed?

Possible Side Effects and Safety Information

The safety profile for Flavamed, containing ambroxol hydrochloride, is formally categorized according to frequency and physiological impact, as established by regulatory documents.

Frequency-Classified Adverse Reactions

Adverse effects are grouped into standard regulatory frequency categories:

  • Common (ge 1/100 to <1/10): This group includes sensory changes like dysgeusia (altered taste), oral hypoesthesia (numbness in the mouth), and general disturbances such as nausea.
  • Uncommon (ge 1/1000 to <1/100): Reported effects include vomiting, diarrhoea, abdominal pain, dyspepsia, dry mouth, and fever.
  • Rare (ge 1/10,000 to <1/1000): Effects such as general hypersensitivity reactions, rash, and urticaria are classified as rare.

Serious Adverse Reactions and Systemic Constraints

Although the frequency is Not Known, official labeling documents report the potential for Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, and severe allergic reactions such as anaphylactic shock and angioedema.

Safety notes specify required caution for specific patient groups. Use is not recommended during the first trimester of pregnancy or during breastfeeding. Individuals with severe renal or hepatic impairment require particular care due to the risk of metabolite accumulation. Additionally, the label advises against the concomitant use of ambroxol with cough suppressants because of the potential for the accumulation of secretions in the airways.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose with Flavamed (Ambroxol Hydrochloride) requires prompt medical attention, as mandated by regulatory guidance. The officially documented clinical manifestations of overdose are generally consistent with an extension of the medicine’s known undesirable effects.

Clinical Manifestations Emergency Response
Gastrointestinal: Nausea, vomiting, diarrhea, dyspepsia, pyrosis, and throat irritation are the most common reported signs. Seek immediate medical attention or consult a doctor immediately for suspected overdose.
Systemic: Short-term restlessness. More severe effects, such as hypotension (drop in blood pressure), may be expected following extreme overdosage based on official data. Management is symptomatic and supportive treatment because no specific antidote is known for Ambroxol.

The regulatory profile states that no severe signs of intoxication are commonly observed, with the most serious effects reserved for instances of very high overdosage. Patient observation is required following any overdose event. Treatment procedures like gastric lavage or induced vomiting are not generally indicated but are considered conditional measures only for extreme exposure within the first few hours, strictly as defined in official prescribing information.

Therapeutic Uses of Flavamed

What Flavamed Treats: Main Uses and Benefits

Flavamed is primarily used for secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport. The medication generally targets the symptom cluster of ineffective productive cough where the phlegm is excessively thick, viscid, or difficult to expel. It supports patients in situations involving certain distressing symptoms by offering symptomatic relief that helps ease the overall burden of persistent, taxing cough episodes.

The medication is commonly applied in clinical settings that involve acute episodes of respiratory illness, recurrent manifestations of chronic conditions, or when symptoms cluster into patterns requiring supportive management. Adults, adolescents, and children may find this medication relevant when they experience difficulty expectorating the accumulated sputum. The core benefit is applied in addressing symptoms that interfere with daily comfort, such as a strained, difficult cough. This contributes to improved day-to-day comfort and assists the patient with maintaining functional stability during symptomatic periods.


Quick Fact: Relief for Viscid Productive Cough

The core symptomatic application includes Acute Bronchitis, Chronic Bronchopulmonary Diseases, and other conditions characterized by thick, difficult-to-clear mucus.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Flavamed

Regulatory documents define who can and cannot use the medicine through classifications of allowed, restricted, or prohibited populations.

Populations for Whom Use is Contraindicated

  • Hypersensitivity: Use is strictly contraindicated in patients with known allergy to the active substance, ambroxol hydrochloride, or to any of the product's excipients.
  • Metabolic Disorders: Contraindicated for individuals with rare hereditary intolerances, such as fructose intolerance (for liquid formulations containing sorbitol) or galactose/lapp lactase deficiency (for tablet formulations containing lactose).

Age-Related Eligibility Rules

Age Group Eligibility Status
Adults & Adolescents Generally allowed (over 12 years)
Children (2 to 12 years) Allowed for mucolytic therapy
Children under 2 years Not recommended or contraindicated

Conditional Use and Restrictions

  • Organ Function: Use requires caution in patients with severe renal or hepatic impairment, as accumulation of the drug or its metabolites is expected.
  • Comorbidity: Caution is required in patients with a history of peptic ulceration or compromised airway motility.
  • Pregnancy & Lactation: Use is not recommended during breastfeeding and should be avoided during the first trimester of pregnancy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific interaction constraints for ambroxol hydrochloride, the active substance in Flavamed. These constraints govern co-administration based on documented pharmacodynamic and pharmacokinetic outcomes.

Pharmacodynamic and Restriction-Based Interactions

Interacting Product Category Official Restriction Statement Outcome Classification
Antitussives (Cough Suppressants) Not recommended for co-administration (e.g., codeine). Pharmacodynamic Interaction: Risk of cough reflex depression leading to excessive sputum accumulation and potential airway obstruction.

Exposure-Modifying and Population-Specific Interactions

Interacting Substance Category Interaction Outcome Population-Specific Restriction
Certain Antibiotics Co-administration facilitates increased concentration and enhanced penetration into lung tissue. Severe Renal or Hepatic Impairment: Risk of metabolite accumulation and reduced clearance is expected, requiring adjustment to the dosing interval.
(e.g., Amoxicillin, Doxycycline) This is considered a documented enhancement of tissue exposure. No clinically significant adverse drug-drug interactions have been generally observed outside of these documented patterns.

The drug's official interaction profile primarily focuses on avoiding combinations that impede the necessary clearance of mucus, such as those involving antitussives. Conversely, the profile also details the enhancement of exposure for certain antibiotics in bronchial secretions. The final key constraint pertains to the drug's metabolic clearance, which necessitates administration considerations for individuals with pre-existing severe organ impairment.

Mechanism of Action

The mechanism of action for Flavamed (Ambroxol Hydrochloride) centers on the modulation of the respiratory tract's physiological clearance systems by acting on three distinct but interconnected biological domains.


Mucus Viscosity Reduction (Mucolysis)

This domain addresses the highly cohesive nature of respiratory secretions. The active ingredient chemically induces the depolymerization of complex acid mucopolysaccharide fibers—the molecular structures primarily responsible for high viscosity. This targeted breakdown reduces the internal cohesion of the phlegm, resulting in a physiological reduction in mucus thickness.


Surfactant and Airway Anti-Adhesion

This mechanism centers on surface dynamics within the airways. Ambroxol acts as a secretagogue, promoting the synthesis and release of pulmonary surfactant from Type II pneumocytes. Surfactant functions to lower the surface tension, which, in turn, reduces the adhesiveness of the mucus to the bronchial epithelium, preventing its tight fixation to the airway wall.


Enhanced Mucociliary Transport

This is the culminating physiological cascade that integrates the previous two actions. By modulating secretions to be both thinned (low viscosity) and non-adherent (low surface tension), the drug alters the physical properties necessary for the mucociliary transport pathway. This system-level enhancement promotes the systematic mobilization and removal of secretions.

Dosage and Administration Information

Flavamed, which contains ambroxol hydrochloride, is administered via the oral route for all approved formulations, including tablets, syrups, and solutions. Dosing for adults and adolescents aged 12 years and over is typically phased to establish the therapeutic level. The standard regimen begins with 30 mg taken three times daily (TID) for the first two to three days, after which the schedule transitions to a maintenance dose of 30 mg twice daily (BID). The maximum daily dose may be increased up to 120 mg, divided into two 60 mg doses, if required for enhanced effect.


For administration, the medicine is preferably taken after a meal (postprandially) and must be accompanied by sufficient liquid, such as a glass of water, to support its function. There are age-tiered rules for pediatric use: children 6 to 12 years are prescribed 15 mg two to three times daily, while children under 6 years should use liquid formulations, as the 30 mg tablet strength is considered unsuitable.


Therapy should not be continued for longer than four to five days without medical re-evaluation if symptoms do not improve or worsen. For sustained-release capsules, a special procedural condition requires the capsule to be swallowed whole, without being crushed or chewed, to preserve its intended release profile. A reduction of the dose or an extension of the interval between doses is required for patients with known severe hepatic or renal impairment. If a dose is missed, patients are instructed to resume the regular dosing schedule at the next usual time and are warned not to double the dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flavamed

Flavamed, which contains the active ingredient ambroxol, has been the subject of research that was studied in conditions where symptoms may vary in intensity and mucus is thick and difficult to clear. The available evidence, primarily sourced from randomized controlled trials (RCTs) and systematic reviews, describes the patterns and changes observed in patients studied under specific clinical conditions.


Evidence for Symptomatic Research in Acute Bronchopulmonary Diseases

Research primarily involved short-term, randomized controlled trials (RCTs) and systematic reviews, which compared ambroxol to placebo and other specified treatments in the context of productive cough associated with thick mucus. These studies were designed to monitor patient-reported outcomes describing perceived discomfort related to cough frequency, cough severity, and the difficulty of expectorating phlegm.

Findings describe patterns observed in the studies related to how symptoms changed in the observed populations. However, these findings describe group patterns, not personal outcomes. A key limitation is that follow-up durations were limited, meaning the data primarily focuses on the immediate measurement of symptoms over short time intervals.


Evidence Structure for Chronic Respiratory Conditions

Research for conditions characterized by fluctuating or episodic manifestations like chronic bronchitis was investigated using extended-duration randomized controlled trials and subsequent meta-analyses. These studies were designed to monitor outcomes related to systemic or functional imbalance, such as the frequency of acute changes (exacerbations) in the disease.

Studies monitored the time to first acute change and also examined outcomes reflecting daily functioning. However, data show patterns related to changes in objective lung function measures, such as FEV1, and findings were inconsistent across different trial populations. Long-term effects are not fully established regarding the application of ambroxol as a long-term therapy across all chronic respiratory conditions.


Research in Special Populations

Research has been conducted in specific subgroups, including pediatric patients of various ages. However, data for certain groups remain insufficient. Specifically, authoritative regulatory reviews have highlighted that evidence quality varies across studies and that there is limited information to fully establish the effect of ambroxol for the secretolytic indication in children below 6 years of age. This suggests that research is ongoing to provide clearer context for the use of ambroxol in these populations.

Key Studies & References

  1. An overview of efficacy and safety of ambroxol for the treatment of acute and chronic respiratory diseases with a special regard to children

Frequently Asked Questions (FAQ)

Common questions about Flavamed (FAQ)


Q: How quickly does Flavamed typically start working after the first dose?

According to official product information, the active substance, ambroxol, typically reaches its peak concentration in the blood plasma after approximately 2 hours following a single oral dose. This indicates the time when the active substance typically reaches its highest level in the bloodstream.


Q: Why is it recommended to stop taking Flavamed after 4-5 days if symptoms don't improve?

The medicine is generally intended for short-term use. Official regulatory texts specify that therapy should not continue for longer than four to five days without mandatory medical re-evaluation if symptoms persist or worsen. This duration limit is in place to ensure a mandatory medical re-evaluation occurs.


Q: Does Flavamed work for dry cough, wet cough, or both?

Flavamed is indicated for the mucolytic treatment of productive cough associated with acute or chronic lung diseases. This use is specifically targeted at conditions where there is abnormal, thick mucus secretion.


Q: Can Flavamed be taken on an empty stomach?

Official product documents state that the medicine is recommended to be taken after meals (postprandially).


Q: Are there any reports about Flavamed causing gastrointestinal discomfort like vomiting or diarrhea?

Yes. Regulatory documents report that general gastrointestinal disturbances, including vomiting and diarrhea, are classified as uncommon side effects. Nausea is also listed as a common side effect.


Q: Does the effectiveness of Flavamed rely on having a specific type of infection or only on the presence of mucus?

Official information indicates that Flavamed is for the symptomatic management of respiratory conditions. The primary indication is the management of symptoms associated with abnormal, thick mucus secretion.


Q: Is it possible to take Flavamed with anti-inflammatory drugs (NSAIDs)?

Official regulatory documents state that no clinically significant adverse drug-drug interactions have been generally observed outside of the documented patterns. It is important to review the full interactions section for known constraints, such as avoiding co-administration with cough suppressants.


Q: Is it necessary to drink a lot of water when taking Flavamed?

Official administration instructions emphasize that the medicine must be accompanied by sufficient liquid, such as a glass of water. The requirement to take it with sufficient liquid is specified to support the medicine's proper function.


Q: Can Flavamed be taken alongside common cold or flu remedies?

While regulatory texts state that no major adverse interactions have been generally observed with many other drugs, co-administration with cough suppressants (medicines that stop you from coughing) is not recommended. This combination is not recommended due to the potential for excessive sputum accumulation in the airways.


Q: Are there any known interactions between Flavamed and commonly used antibiotics?

Regulatory information indicates that co-administration with certain antibiotics (such as amoxicillin, doxycycline, and cefuroxime) has been documented. Co-administration has been documented to increase the concentration of these antibiotics in lung tissue.


Q: Is Flavamed available in different forms, such as tablets, syrup, or effervescent tablets?

Official product information describes the medicine as available in various oral forms, including standard tablets and oral solution (syrup). The availability of other specific formulations, such as effervescent tablets, may vary by region.


Q: Are there any specific sugars or ingredients in Flavamed (like lactose or sorbitol) that people should be aware of?

Yes, some tablet formulations contain the sugar lactose, and certain liquid formulations contain sorbitol. Use is contraindicated (not allowed) for individuals with known rare hereditary intolerances related to these specific excipients.


Q: Is it true that Flavamed's active ingredient, ambroxol, is being studied for other conditions besides cough?

Official research evidence primarily focuses on the medicine's function in the context of acute and chronic respiratory diseases. The core indication remains its use as a secretolytic agent.


Q: What is the typical duration of treatment with Flavamed before needing to consult a doctor?

The medicine is classified for short-term use. Patients are advised in regulatory documents not to take it for longer than four to five days without consulting a doctor, especially if symptoms have not improved.


Q: Is there a concern about using Flavamed if a person has a rare bronchial condition like primary ciliary dyskinesia?

Official warnings state that caution is required for patients with rare bronchial conditions that involve compromised airway motility, which includes conditions like ciliary dyskinesia. Caution is required for this group due to the potential for the accumulation of secretions in the airways.


Q: Are there any special storage instructions for Flavamed tablets or syrup?

Yes. Regulatory guidelines specify that both tablets and liquid must be kept in their original container to protect them from light and moisture. Additionally, they should be stored at a temperature not exceeding 30 C.


Q: Why do some people feel a numbness or tingling sensation in their mouth or throat when using Flavamed?

Official safety profiles list sensory changes such as oral hypoesthesia (numbness in the mouth) and dysgeusia (altered taste) as common side effects. This is a known effect associated with the active substance.


Q: Can Flavamed be taken if I am also using anti-allergy medications like antihistamines?

Official regulatory documents state that no clinically significant adverse drug-drug interactions have been generally observed outside of the documented patterns (e.g., antitussives). It is important to review the full interaction section for known constraints.


Q: Can Flavamed be divided into smaller doses, or should the tablet be taken whole?

Standard tablets are often manufactured with a score line, which helps in breaking them. However, it is a key regulatory instruction that sustained-release formulations must be swallowed whole and not crushed or chewed.


Q: Is there any research indicating how ambroxol affects fertility?

Based on preclinical safety data reviewed by regulatory authorities, non-clinical studies do not directly or indirectly indicate any adverse effects on fertility associated with the active substance.


Q: How long can a person safely use Flavamed continuously?

Regulatory information specifies that the medicine is for short-term use. Patients are advised not to take it for longer than four to five days without obtaining a medical re-evaluation, especially if symptoms persist.


Q: What should be done if someone accidentally takes more than the recommended amount of Flavamed?

Official documents addressing overdose state that a person should seek emergency medical treatment or consult with a doctor or pharmacist if more than the recommended amount is accidentally taken.


Q: Is it true that Flavamed may interact negatively with some older types of pain relievers?

Official documents state that no clinically significant adverse interactions with other drugs have been generally observed outside of the documented constraints. The primary restriction is against co-administering the medicine with cough suppressants.


Q: Can Flavamed affect the ability to drive or operate machinery?

Official regulatory texts have stated that the medicine has no influence on the ability to drive and use machines.

How should Flavamed be stored and disposed of?

Flavamed (Ambroxol Hydrochloride) must be stored and disposed of according to specific regulatory requirements to maintain product quality and safety.

Storage Conditions

Requirement Official Instruction
Temperature Store at a temperature not exceeding 30 C (86 F).
Protection Keep the medicine in its original container and outer carton to protect it from light and moisture.
Child Safety Keep this medicine out of the sight and reach of children.

Disposal Instructions

Expired or unused Flavamed must not be disposed of via wastewater or household waste. Disposal must occur according to local requirements for pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flavamed found in:

A-Z Index: